Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

News

2023-03-01
Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes
2022-04-13
Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of Imotope™ IMCY-0141 for Multiple Sclerosis
2022-03-14
Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference
2022-01-13
Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study
2021-11-03
Imcyse Appoints Gene Mack, MBA as Chief Financial Officer

©imcyse 2023